“We do not expect any decision until after the new year,” a spokesperson for the European Commission told the Financial Times. It is the second such delay this year.
What was initially thought to be a June conclusion was first pushed back in early May.
“We will not sacrifice the rule of law or the quality of our work to speed up the process,” European Commissioner for Competition Margrethe Vestager said at the time, blaming the delay on the “time consuming” process of gathering information.
While Apple has long maintained that its arrangement with Ireland is entirely legal, the company is nevertheless preparing should the decision go the other way.
“If the European Commission were to conclude against Ireland, it could require Ireland to recover from the company past taxes covering a period of up to 10 years reflective of the disallowed state aid, and such amount could be material,” the company wrote in a recent quarterly report.
In addition to Apple, the Commission is also investigating similar arrangements between Amazon and Luxembourg as well as Starbucks and the Netherlands.
Full content: The Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan